CADL
Candel Therapeutics Inc
NASDAQ: CADL · HEALTHCARE · BIOTECHNOLOGY
$6.18
-0.32% today
Updated 2026-04-29
Market cap
$476.11M
P/E ratio
—
P/S ratio
436.42x
EPS (TTM)
$-0.72
Dividend yield
—
52W range
$4 – $8
Volume
1.6M
Candel Therapeutics Inc (CADL) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-5.18M | $-9.07M | $-22.22M | $-31.42M | $-34.24M | $-27.02M | $-38.31M |
| Capital expenditures | $159000.00 | $1.48M | $1.83M | $1.30M | $457000.00 | $16000.00 | $587000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $400000.00 | $2.11M | $2.96M | $2.31M | $3.09M | $5.31M | $3.82M |
| Free cash flow | $-5.34M | $-10.55M | $-24.05M | $-32.72M | $-34.70M | $-27.04M | $-38.90M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $47.75M | — | — | — | — |